cyrilzakka/clinical-trials huggingface dataset:
Combine Effect Of Myofascial Release Technique and Ocular Muscle Exercise Among University Students

The current study aim to determine the effect of myofascial release technique and ocular muscle exercise to release eye strain headache in myopic students.

This study aim to reduce eye strain headache to improve quality of life and student academic performance. This study will enable the students to to work on digital device for a long period of time without any discomfort.

According to recent researches MFR technique used to relax the muscles tension in muscles and fascia. This technique also enhance ROM. In this technique Apply gentle and sustain pressure on muscle start with light pressure gradually increase as it tolerated move the fingers along the length of muscle during apply pressure to take deep breath to help relax and facilitate the release.

Previous study showed a significant improvement in reduction of the number of headache days (p \< 0.001) and the headache pain level (p \< 0.001) following treatment.

The other intervention of this study is the ocular muscle exercise. Previous study showed that strengthening neck exercises like isometric neck exercise improve muscular strength and it is also delivering long term treatment effect on cervical pain.

This study divide in to two groups. Group A (experimental group) and Group B (control group)Patient in group A will receive ocular muscle exercise which is consist of three exercise like palm exercise, blinking exercise, pencil pushup exercise This group will also receive myofascial release technique on sternocleidomastoid muscle and upper trapezius muscles. Patient in group B will receive ocular muscle exercise and neck isometric exercise.

This study will manage the musculoskeletal and visual aspects of headaches and eye strain by combining myofascial release treatments with eye exercises. This study will contribute to reduce the eye strain headache and improve their quality of life and improve students' academic performance during class room and online learning.

Eligibility Criteria:
Inclusion Criteria:

* Age = 20- 30 years old
* Gender= male / female
* Diagnosed of Mild (-0.50 to -3.0 D) and moderate ( -3.0 to -6.0 D) myopia
* Unilateral or bilateral headache with mild or medium intensity
* Pain around eyes, forehead and temples
* Headache with neck stiffness or pain
* Headache increase with visual activity such as reading, using computer or cell phone.
* Headache associate with triggers in sternocleidomastoid, upper trapezius
* Positive convergent test (13)

Exclusion Criteria:

* History of genetic disease
* History of refractive surgery
* Wear contact lenses
* Headache associate with photophobia
* Headache associate with phonophobia
* History of neck trauma
* Cervical radiculopathy, herniated disc, arthritis
* Pain aggravated by movements of head
Methylphenidate in ADHD With Trichotillomania

This study will evaluate the safety and effectiveness of methylphenidate in treating attention deficit hyperactivity disorder (ADHD) in children with both ADHD and trichotillomania.

Trichotillomania is an impulse control disorder. There is growing evidences of the involvement of dopaminergic neurotransmission in the pathophysiology of trichotillomania. Reported increase in the prevalence of ADHD among patients with impulse control disorders, such as pathological gambling as well as trichotillomania, may result from the overlapping pathophisiological background. It is hypothesized that in cases of ADHD comorbid with trichotillomania methtylphenidate treatment will exhibit beneficial effects in both the ADHD and the hair pulling.

Thirty children and adolescents aged 6-18 years, diagnosed with ADHD and trichotillomania, will receive MPH monotherapy treatment for a period of 12 weeks, targeting both ADHD and trichotillomania symptoms as rated by the ADHD- rating scale (ADHD-RS) and by the Massachusetts General Hospital Hair Pulling Scale and Clinical Global Impression-Severity (CGI) scale. The rating scales will be assessed at baseline and at the endpoint (after 12 weeks).The side effects will be monitored via weekly spontaneous self reports by each participant. All results will be expressed as mean ±SD. Student's paired t-test and ANOVA test will be used as appropriate.

Eligibility Criteria:
Inclusion Criteria:

* DSM-IV Diagnosis of trichotillomania
* DSM-IV diagnosis of ADHD
* Has not taken stimulants or alpha-adrenergic medications for more than 2 weeks prior to entering the study.

Exclusion Criteria:

* History of moderate or severe adverse event, related to MPH
* History of any psychotic disorder
* Current drug abuse, acute psychotic or affective disorder
Homeopathic Treatment of Post-acute COVID-19 Syndrome

To determine whether an individually prescribed homeopathic medicine has an effect greater than a placebo and is a viable treatment option to improve fatigue and quality of life for patients suffering from the symptoms of Post-acute COVID-19 Syndrome. The researchers hope to achieve this goal by conducting a clinical trial that is scientifically rigorous and clinically relevant. Expected results of this pilot study will be to obtain sufficient experience and preliminary feasibility data to justify a larger clinical trial of this hypothesis.

The researchers objectives for the study are to: 1) identify efficient means of recruiting subjects, 2) test and refine the initial study design and treatment protocol, 3) evaluate the instruments for assessing treatment outcomes, 4) estimate sample sizes that will be required in the full-scale trial, 5) determine which homeopathic medicines are most often prescribed for this syndrome, and 6) determine whether there is a measurable effect size difference or positive trend in reduction of symptoms in patients treated with homeopathy.

Eligibility Criteria:
Inclusion Criteria:

* Ages 18-64
* Any ethnicity
* Adequate cognitive function to be able to give informed consent
* Technologically competent to complete web forms and perform video calls
* Positive PCR test (polymerase chain reaction) result for SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2)
* Persistent fatigue for a minimum of 60 days since diagnosis of Covid-19.
* A fatigue score above 21 in the Fatigue Assessment Scale upon enrollment
* Willing to fill out regular questionnaires
* Willing to use homeopathic medicines

Exclusion Criteria:

* Clinically significant kidney, heart, or hepatic impairment as determined by clinical judgment

  * Previous hospitalization in ICU for Covid-19
  * Diagnosis of Chronic Fatigue Syndrome, Fibromyalgia, or Lyme disease prior to Covid-19
  * Chronic psychiatric illness or neurological illness prior to Covid-19 diagnosis Taking opioid analgesics, opioid dependence or undergoing treatment for substance abuse or addiction
  * Taking steroid medication or immunosuppressive medications
  * Suspected or confirmed pregnancy or breastfeeding
  * Active cancers
  * Current treatment by a homeopathic practitioner
  * Initiation of another treatment for Long Covid within the past 2 months
Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita

This study evaluates the safety and efficacy of PTX-022, topical rapamycin, in the treatment of adults with moderate to severe Pachyonychia Congenita.

This study includes four-parts, and if a participant completes all parts, the participant will have received at least 3-months of PTX-022 treatment.


Eligibility Criteria:
Inclusion Criteria:

* Adult patients, 18 years or older
* Diagnosed Pachyonychia Congenita (PC), genetically confirmed
* Moderate to Severe PC
* Able and willing to comply with all protocol-required activities
* Willing and able to provide written informed consent

Exclusion Criteria:

* Any significant concurrent condition (including involving the inferior to the ankle) that could adversely affect participation.
* Any intentional changes in the patient's daily activities (associated with standing, walking and keeping balance), not resulting from an improvement in the patient's condition due to treatment.
* Patient's deemed by the investigator as unwilling or unable to remain compliant with all tests and procedures, including adherence to study drug administration and other protocol-required activities.
Helix Research Network

The Helix Research Network ("HRN") is a network of academic, public, and/or private healthcare organizations that are committed to advancing medical research and improving human health through large-scale genomics research and acceleration of the integration of genomic and other omics data into clinical care.

The network will create a large-scale clinicogenomics dataset, which will support research to discover molecular and genetic determinants of disease risk, disease progression, treatment response, health economic outcomes, social or behavioral determinants of health, targets for therapeutic intervention, risk stratification, clinical implementation, and other clinical indicators of interest. This clinicogenomics dataset will be used to reveal molecular and/or genetic factors that could improve the diagnosis or medical treatment of individual participants and includes a process to share individual results with participants. Participants will also receive annual reports on study outcomes and the impact of HRN, as such information becomes available.

Institutional membership in HRN will consist of Helix and member healthcare systems (herein referred to as "HRN Member Site(s)"). The Helix Research Network is a multi-center research program that will enroll an unlimited number of participants. Participants will be recruited concurrently from HRN Member Sites. In some cases, HRN Member Sites may recruit participants from multiple clinical sites. Participants who meet the enrollment criteria established in this protocol will be enrolled if they or their legally authorized representative(s) provide informed consent in accordance with all applicable regulations and sIRB requirements. Participants will be enrolled until withdrawal from the study or end of the study. Participants may be recruited at any point during the study period, until the recruitment goals established by the protocol are met.

Eligibility Criteria:
Inclusion Criteria:

* 18 years and older
* Willing and able to comply with all aspects of the protocol

Exclusion Criteria:

* History of allogenic bone marrow transplant
* History of allogenic stem cell transplant
* Anything that would place the individual at increased risk or preclude an individual's: 1) full compliance with study requirements; or 2) completion of the study based on the assessment from local consenting and enrolling Investigators.
Compare the Effect of Exercise Program Plus Dry Needling Versus Elastic Taping

Low back pain is a common musculoskeletal health condition in society. It is a leading cause of disability globally and has created a significant burden in terms of work disability and high healthcare costs.

Studies on the treatment of combined therapies for non-specific low back pain are scarce, so it is not known in depth which intervention is the best for reducing pain. For this reason, the objective of this study was to evaluate and compare the effect of physical exercise plus dry needling versus physical exercise plus elastic bandage. For this, a randomized clinical trial was carried out with a total of 22 people, where pain was evaluated using the ENA scale and functionality using the Oswestry test. Participants received CORE stabilization exercises. CORE stability training has become a popular training trend and has begun to be applied in rehabilitation programs and sports medicine (1).

The expected results of the study are that the group that receives the physical exercise intervention plus dry needling will have better results in reducing the pain and functionality variable, evaluated with ENA and Oswestry in 4 sessions.


Eligibility Criteria:
Inclusion Criteria:

* Workers of the University of the Americas, Santiago Centro Campus, Echaurren and República Headquarters

Exclusion Criteria:

Not having a diagnosis of cancer,

* Hernia of the nucleus pulposus with neural symptoms,
* Pregnant
* History of recent surgery (\<6 months)
* History of tumor
* History of spinal fracture
* People with belonephobia
Minimal Surgical Treatment for Obstructive Sleep Apnea (OSA)

Obstructive Sleep apnea carries a variety of complications and implications. While the disease could be treated using continuous positive airway pressure (CPAP) and lifestyle changes, many patients find it difficult to adjust to the mask, and turn to surgical options. The conventional surgical options to date ranges from radical (UPPP) to individualized, with or without Drug-induced sleep endoscopy (DISE). Previous studies showed that dise directed surgery can be useful for specific conditions. No trials were found to test in-office encompassing minimal invasive surgical treatment (RF palatoplasty , RF tonsillotomy, RF turbinectomy, and RF base-of-tongue reduction) as a viable alternative..


Eligibility Criteria:
Inclusion Criteria:

* Patients suffering from OSA, defined as AHI \> 5

Exclusion Criteria:

* Patients who can use CPAP.
* Patients suffering from confounding factors with higher risk (Coagulation problems, Heart conditions, chronic obstructive pulmonary disease (COPD), or other dangerous conditions as decided by the surgeon)
* Patients suffering from other problems aggravating the OSA (Respiratory, Neurologic conditions)
Reference Range for abioSCOPE® Device With the PSP Assay in a Generally Healthy Adult Population

This is a single center, prospective, biomarker-result-blinded observational study evaluating immunoassay measurements of pancreatic stone protein (PSP) performed on Abionic's abioSCOPE device with the PSP assay on generally healthy adults representative of the US population.


Eligibility Criteria:
Inclusion Criteria:

1. Male or female, aged ≥ 18 years.
2. Apparently healthy as determined by a subject questionnaire.

Exclusion Criteria:

1) Current diagnosis, or history, of any underlying major medical condition determined by the investigator, including but not limited to:

1. Heart disease
2. Stroke
3. Renal disease
4. Liver disease
5. Pancreatic disease
6. Chronic obstructive pulmonary disorder
7. Bleeding disorders
8. Hypercalcitoninemia
9. HIV AIDS
10. Receiving antibiotic therapy
11. Suspected infection
12. Immunosuppression

    2) Underwent procedures related to sepsis, or diagnosed with sepsis, within the last 12 months.

    3) Current diagnosis of uncontrolled hypertension, hypotension, or diabetes.

    4) Diagnosis of bacterial, fungal, or malaria infection within the last 3 months that required antimicrobial treatment.

    5 )Experienced severe trauma, surgery, cardiac shock, or severe burn within the previous 3 months requiring medical care.

    6) Current diagnosis of cancer within the last 12 months.

    7) Received immunotherapy to stimulate or inhibit cytokines within the last 12 months.

    8) Hospitalization for more than 24 hours within the last 3 months.

    9) Reported as currently pregnant or nursing a child

    10) Unable or unwilling to provide the required blood sample for testing.

    11) Any other criteria that, in the opinion of the investigator, would render the participant unsuitable for inclusion in the trial.
Effect of Acute and Sub-acute Administration of Gluten on Extra-intestinal and Gastrointestinal Symptoms in Healthy Subjects

The investigators will investigate the effects of acute and sub-acute administration of gluten on mood, intestinal permeability, gastrointestinal symptoms and gut peptide levels in healthy volunteers (HV).


Eligibility Criteria:
Inclusion Criteria:

* Body Mass Index (BMI) of 20 - 25 kg/m2
* Stable body weight for at least 3 months prior to the start of the study

Exclusion Criteria:

* Medical

  * Coeliac disease (excluded either by absence of the HLA-DQ2 and HLA-DQ8 haplotype or by a normal duodenal biopsy (Marsh 0) performed at endoscopy while on a gluten containing diet in individuals expressing the HLA-DQ2 (human leukocyte antigen) or HLA-DQ8 haplotype)
  * Abdominal or thoracic surgery. Exception: appendectomy
  * Gastrointestinal, endocrine or neurological diseases
  * Cardiovascular, respiratory, renal or urinary diseases
  * Hypertension
  * Diagnosed food or drug allergies
* Psychiatric disorders
* Eating disorders
* Depressive disorders
* Anxiety disorders
* Psychotic disorders
* Restraint or emotional eating
* Dieters, especially no gluten-free diet or a diet low on gluten
* Medication on a regular basis, exception: oral contraception
* Smoking
* History of cannabis use or any other drug of abuse for at least 12 months prior to the study
* Alcohol abuse (more than 21 units of alcohol for men, more than 14 units for woman per week)
* Pregnant or breastfeeding women
Cardiac Changes After Effective Dose Carbetocin for Elective Caesarian Section

The goal of this project is to examine the cardiac symptoms and physiologic changes after administration of a reduced dose of carbetocin in participants undergoing elective cesarian section.

* Does reduced dose carbetocin (50mcg) have fewer cardiac side effects than usual dose carbetocin (100mcg) when comparing patient reported symptoms, ECG changes and troponin increases?
* Is there a relationship between patient reported cardiac symptoms after carbetocin administration and subjective measures of cardiac ischemia (ECG changes and troponin increases? Researchers will compare 50mcg of carbetocin to the control group of 100mcg of carbetocin in patients undergoing elective cesarian section.

Participants will:

* Be given 50mcg or 100mcg of carbetocin during cesarian section
* Asked to report cardiac symptoms
* Be assessed for ECG changes and blood loss using standard of practice monitoring
* Have a troponin I blood test completed after delivery


Eligibility Criteria:
Inclusion Criteria:

* Undergoing elective cesarian section
* Primary and repeat cesarian section

Exclusion Criteria:

* Prior and current cardiovascular co-morbidities including pre-eclampsia
* BMI greater than 50
* Pre-existing bleeding disorders
* Allergy to carbetocin
* Age under 18
PANCREATIC CANCER: DYNAMIC ASSESSMENT AT ALL STAGES OF TREATMENT

The study consists of a 25 ml blood sample collection:

* Before the start of treatment
* Approximately 2 months after the start of induction chemotherapy
* At the end of induction chemotherapy
* Prior to local treatment (radiotherapy, surgery)
* At the time of tumor progression

Collection of tumor material:

* During the initial diagnostic biopsy
* On the operating room in case of surgery
* At tumor biopsy in case of recurrence or progression (optional) As well as the completion of a questionnaire at inclusion.


Eligibility Criteria:
Inclusion Criteria:

* Non-metastatic pancreatic adenocarcinoma that is not immediately resectable (borderline and locally advanced tumors according to the NCCN 2020 classification)
* No previous treatment with surgery or chemotherapy
* Age \> 18 years
* General condition WHO 0-2 (patient whose general condition can allow medical treatment or surgery)
* Therapeutic management at the Paoli-Calmettes Institute
* Signature of the informed consent specific to the PANDORE-PANC study
* Patient affiliated to a social security system or benefiting from such a system

Exclusion Criteria:

* Metastatic disease
* Pancreatic tumor of a histological type other than adenocarcinoma
* Other tumor under treatment or for which treatments have been completed for \< 1 year
* Pregnant or breastfeeding women
* Person in an emergency situation
* Person of legal age under legal protection (guardianship, curatorship or safeguard of justice) or unable to give consent.
Study of Oral Vorinostat in Combination With Topotecan in Patients With Chemosensitive Recurrent SCLC

The purpose of this study is to evaluate the maximum tolerated dose, the activity and the safety profile of the combination of vorinostat and topotecan in patients with recurrent small cell lung cancer


Eligibility Criteria:
Inclusion Criteria:

* Histologically or cytologically proven diagnosis of SCLC;
* Limited or extensive-stage disease in patients who have received a single chemotherapy regimen or combined modality (chemotherapy + chest radiotherapy) regimen and relapsed after completion of first-line chemotherapy (sensitive relapse);
* Age \>/= 18 years;
* ECOG Performance Status 0-2;
* Life expectancy of at least 12 weeks;
* Measurable lesions according to RECIST criteria;
* Adequate cardiac, hepatic, renal, and bone marrow function;
* Written informed consent.

Exclusion Criteria:

* Prior treatment with an HDAC inhibitor;
* Symptomatic and/or unstable pre-existing brain metastases;
* Superior Vena Cava Syndrome;
* Spinal cord compression;
* Severe or uncontrolled medical diseases (Hypertension, diabetes, congestive heart failure, myocardial infarction within 6 months of study, chronic renal disease, or active uncontrolled infections);
* Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ;
* Pregnant or breastfeeding women.
Telehealth to Reduce Mental Health in Family Caregivers

The overarching goal of this project is to evaluate if evidence-based interventions can reduce PDG, burden, and stress in informal caregivers of individuals with dementia when provided over telehealth.

Aim 1: Examine the effects of two individual evidence-based therapies for informal caregivers of dementia patients over telehealth.

Eligibility Criteria:
Inclusion Criteria:

* Participants must be informal caregivers (e.g., spouse; child; close friend) of individuals with dementia
* Informal caregivers can be family members or close friends
* Adults (18 to 89 years old) who read, write, and speak in English
* Mental Health Diagnosis (e.g., Generalized Anxiety Disorder; Major Depressive Disorder

Exclusion Criteria:

* Formal caregivers (who are being paid to take care of the patient)
* Any informal caregivers with cognitive impairment is identified during the assessment.